Assessing the Mechanism & PD Characterization of Conditionally Active Biologics Leveraging the TME to Improve ADC Therapeutic Index - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Assessing the Mechanism & PD Characterization of Conditionally Active Biologics Leveraging the TME to Improve ADC Therapeutic Index

10:00 am - Monday 12th October 2026

Highlighting the benefits and potential of conditionally activated ADCs against traditional conjugate design
Exploring Conditionally Active Biologic mechanism leveraging tumor pH and physiological conditions for ADC activation
Spotlighting PD profiles of conditionally active ADCs to demonstrate improved therapeutic index

Speakers:

Jian Chen

Jian Chen

Director, Translational Research & Preclinical Development

BioAtla